CD8A and cancer: While most of the licensed adjuvant systems mentioned above undeniably raise potent TH2 and humoral immune responses, adequate protection against different infectious pathogens (e.g. M. tuberculosis, dengue virus or Plasmodium falciparum) and cancer requires potent TH1, TH17 and CD8+ T cell immunity (253).